A First in HCV Drugs for Youths

• Autores: Rebecca Voelker
• Localización: JAMA: the journal of the American Medical Association, ISSN 0098-7484, Vol. 317, Nº. 19, 2017, págs. 1942-1942
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Children and teens aged 12 to 17 years who have hepatitis C virus (HCV) infection will have access to the same antiviral medications that are known to eliminate HCV infections in adults.

    Sofosbuvir, marketed as Solvadi, and a combination of sofosbuvir and ledipasvir, marketed as Harvoni, are the first direct-acting antiviral treatments to gain FDA approval for pediatric patients with HCV infection. Direct-acting antivirals decrease HCV levels by preventing the virus from replicating. In most cases, FDA officials said, the drugs cure HCV infection.